NeuroBo Pharmaceuticals (NRBO) Competitors $2.67 +0.10 (+3.89%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NRBO vs. BYSI, GNLX, CASI, ONCO, PMVP, CRVO, ELDN, OVID, CLSD, and MNOVShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include BeyondSpring (BYSI), Genelux (GNLX), CASI Pharmaceuticals (CASI), Onconetix (ONCO), PMV Pharmaceuticals (PMVP), CervoMed (CRVO), Eledon Pharmaceuticals (ELDN), Ovid Therapeutics (OVID), Clearside Biomedical (CLSD), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry. NeuroBo Pharmaceuticals vs. BeyondSpring Genelux CASI Pharmaceuticals Onconetix PMV Pharmaceuticals CervoMed Eledon Pharmaceuticals Ovid Therapeutics Clearside Biomedical MediciNova BeyondSpring (NASDAQ:BYSI) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk. Does the media prefer BYSI or NRBO? In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled NeuroBo Pharmaceuticals'average media sentiment score. Company Overall Sentiment BeyondSpring Neutral NeuroBo Pharmaceuticals Neutral Which has more risk & volatility, BYSI or NRBO? BeyondSpring has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500. Do insiders and institutionals have more ownership in BYSI or NRBO? 40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate BYSI or NRBO? NeuroBo Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 274.53%. Given NeuroBo Pharmaceuticals' higher possible upside, analysts plainly believe NeuroBo Pharmaceuticals is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ANeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, BYSI or NRBO? NeuroBo Pharmaceuticals has lower revenue, but higher earnings than BeyondSpring. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyondSpring$1.88M46.39-$21.03MN/AN/ANeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Does the MarketBeat Community favor BYSI or NRBO? BeyondSpring received 158 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote. CompanyUnderperformOutperformBeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% NeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% Is BYSI or NRBO more profitable? BeyondSpring's return on equity of 0.00% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BeyondSpringN/A N/A N/A NeuroBo Pharmaceuticals N/A -154.04%-109.08% SummaryBeyondSpring beats NeuroBo Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.95M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.785.324.645.01Net Income-$12.47M$153.56M$119.13M$225.46M7 Day Performance-3.96%0.12%0.78%0.37%1 Month Performance-0.74%15.23%5.65%3.57%1 Year Performance-19.35%41.16%36.90%29.42% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo Pharmaceuticals3.3899 of 5 stars$2.67+3.9%$10.00+274.5%-20.5%$21.95MN/A0.008BYSIBeyondSpringN/A$2.26+2.7%N/A+120.4%$88.21M$1.88M0.0080Positive NewsGNLXGenelux2.8379 of 5 stars$2.55+1.2%$22.33+775.8%-79.7%$87.60M$8,000.00-2.6610Analyst ForecastShort Interest ↓News CoverageGap UpCASICASI Pharmaceuticals3.1165 of 5 stars$6.50+11.5%$6.00-7.7%+23.3%$87.11M$23.10M-3.20180News CoveragePositive NewsGap DownONCOOnconetix1.2486 of 5 stars$3.83-4.5%N/AN/A$85.52M$1.46M0.0012News CoveragePositive NewsGap DownPMVPPMV Pharmaceuticals2.7322 of 5 stars$1.66flat$5.75+246.4%-17.7%$85.40MN/A-1.7150CRVOCervoMed1.4605 of 5 stars$13.70+9.0%$53.60+291.2%+43.3%$84.53M$7.14M0.004Short Interest ↑News CoverageELDNEledon Pharmaceuticals3.1772 of 5 stars$3.39-4.2%$16.00+372.0%+292.6%$84.12MN/A-1.6610Gap UpOVIDOvid Therapeutics4.4428 of 5 stars$1.18-2.5%$4.04+242.4%-68.2%$83.75M$390,000.00-2.7460News CoverageCLSDClearside Biomedical2.1328 of 5 stars$1.10flat$5.17+369.7%+32.4%$82.20M$7.52M-2.2030Gap DownMNOVMediciNova0.1688 of 5 stars$1.66-4.0%N/A-11.7%$81.42M$1M-10.3710Analyst Forecast Related Companies and Tools Related Companies BeyondSpring Alternatives Genelux Alternatives CASI Pharmaceuticals Alternatives Onconetix Alternatives PMV Pharmaceuticals Alternatives CervoMed Alternatives Eledon Pharmaceuticals Alternatives Ovid Therapeutics Alternatives Clearside Biomedical Alternatives MediciNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRBO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
